Precision Medicine in Oncology®

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

A retrospective analysis of the phase III GOG-0218 trial has identified a potential biomarker of response for bevacizumab in patients with advanced ovarian cancer.

Treatment with the PARP inhibitor rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer

A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer types aims to test the efficacy of more than 20 drugs simultaneously in an ambitious National Cancer Institute plan to further propel oncology drug discovery into the precision medicine era.

Physicians will now have a new option for some patients who have run out of them, but whose tumors have a genomic variation matching a drug target that is FDA-approved for a different cancer.

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.

The recent approval of nivolumab in the non–small cell lung cancer setting marks a unique shift in the treatment landscape of this malignancy, one that harnesses the patient's own immune system to target the tumors. However, there are challenges in using these agents.

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.

Amid the increasingly public discussion and often vigorous debate surrounding the general topic of precision cancer medicine, there appears to be a misconception of what the term is meant to imply.